MarketsandMarkets Presents High Content Screening Market by Product, Application & End User - Global Forecast to

The report "High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022", The global high-content screening market is expected to reach USD Million by 2022 from USD Million in 2017, at a CAGR of 10.3%.High Content Screening Market Browse 138 market data tables and 42 figures spread through 166 pages and in- depth TOC on "High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022“

Early buyers will receive 10% customization on this report.

The global high content screening market is estimated to grow at a CAGR of 10.3% from 2017 to 2022 to reach USD Million by Market growth can be attributed to the need for cost containment in pharmaceutical R&D, growth in funding for cellular research, and technological advancements in HCS solutions during the forecast period. The rising adoption of label-free technologies and growing focus on stem cell analysis are the key trends in the market. However, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of high-content screening instruments are expected to restrain the market growth to a certain extent. In this report the market is segmented on the basis of product, application, and end user. This report also provides market information on major regional segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Research Methodology Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research and their market revenues were determined through primary and secondary research. Secondary research included the study of the annual and financial reports of top market players, whereas primary research included extensive interviews with the key opinion leaders such as CEOs, directors, and marketing executives. The percentage splits, shares, and breakdowns of the product markets were determined using secondary sources and verified through primary sources. All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data is consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Target Audience Pharmaceutical and biotechnology companies Life sciences instrumentation and reagents companies High-content screening database and software providers High-content screening service providers Business research and consulting firms Academic institutes and government organizations Clinical research organizations (CRO) Government bodies

Based on application, the market is segmented into target identification and validation, primary and secondary screening, toxicity studies, compound profiling, and other applications such as angiogenesis, apoptosis, cell cycle and mitotic index, cell proliferation, endocytosis, protein synthesis, and stem cell differentiation. In 2016, the primary & secondary screening segment dominated the market. The dominant share of this segment is attributed to its wide usage in qualitative assays to exclude the compounds with unintended modes of action, evaluation of bioavailability and lead specificity. Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and contract research organizations. In 2016, the pharmaceutical and biotechnology companies segment accounted for the largest share of the global high-content screening market. The large share of this segment is attributed to the wide usage of HCS in preclinical and clinical studies in the pharmaceutical and biotechnology industries.

North America is the largest market for high-content screening, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. High R&D expenditure, the presence of major lifesciences market players, and government support are some of the factors attributed to the large share of North America in the HCS market. The major players in the market are GE Healthcare (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Becton, Dickinson and Company (U.S.). Some of the other leading players in this market include BioTek Instruments Inc. (U.S.), Bio- Rad Laboratories Inc. (U.S.), Tecan Group Ltd. (Switzerland), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).

Contact Us Contact: Mr. Shelly Singh Markets and Markets UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra , India

About MarketsandMarkets MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. They cover thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.